カテゴリ： GlobalData, アメリカ, 企業調査

Myriad Genetics Inc (MYGN)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Myriad Genetics Inc (MYGN) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011120
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月21日
◆ページ数：75
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that are designed to analyze genes, their expression levels and corresponding proteins to assess a person risk for developing disease later in life, accurately diagnose disease and determine a patient’s likelihood of responding to a particular drug. It also provides an array of pharmaceutical and clinical services. Myriad markets its products through its sales force in Europe and Canada and through distributor agreements in Latin American, Middle Eastern, Asian and African countries. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. Myriad is headquartered in Salt Lake City, Utah, the US.

Myriad Genetics Inc (MYGN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Myriad Genetics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Myriad Genetics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Myriad Genetics Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Myriad Genetics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Myriad Genetics Inc, Medical Equipment, Deal Details 13
Asset Purchase 13
Rules-Based Medicine Acquires Intellectual Property Assets From Satoris 13
Venture Financing 14
Myriad Genetics to Raise Funds through Venture Financing 14
AssureRx Health Raises Additional USD15 Million in Series D Financing 15
AssureRx Health Raises USD7 Million in Venture Financing 16
RainDance Technologies Raises US$20 Million In Series E Financing 18
Crescendo Bioscience Raises US$28 Million In Series D Financing 19
Assurex Health Secures USD12.5 Million in Series C Funding Round 21
Assurex Health Secures USD8 Million in Venture Funding Round 22
Crescendo Bioscience Raises US$56 Million In Series C Financing 23
Sividon Diagnostics Secures Venture Financing 24
AssureRx Plans To Raise US$10 Million In Series A Venture Financing 25
Partnerships 26
Myriad Genetics Enters into Licensing Agreement with Institut Curie and INSERM 26
Myriad Genetics Enters into Licensing Agreement With Children’s Medical Center 27
Myriad Genetics Enters into Licensing Agreement with University of Texas 28
Myriad Genetics Enters Into Licensing Agreement For RAD51C Gene 29
Myriad Genetics Enters Into Licensing Agreement With Chronix Biomedical 30
Sividon Diagnostics Enters into Co-Marketing Agreement with Virchow Labs and Ready Ruixin 31
Myriad Genetics Expands Agreement with AstraZeneca 32
Myriad Genetics Enters Into Co-Marketing Agreement With Sividon Diagnostics For EndoPredict Test 33
Myriad Enters Into Research Agreement With Janssen Research & Development 34
Myriad Genetics Expands Agreement with AstraZeneca for Olaparib 35
DaVita Enters Into Agreement With Myriad Genetics For Protein Biomarker Discovery 36
Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex Biomarker Kits 37
Acquisition 38
Myriad Genetics Acquires Assurex Health for USD348.5 Million 38
Myriad Genetics Acquires Sividon Diagnostics 40
Myriad Genetics Completes Acquisition Of Crescendo Bioscience For US$270 Million 41
Myriad Genetics Acquires Rules-Based Medicine 43
Myriad Genetics Inc – Key Competitors 45
Myriad Genetics Inc – Key Employees 46
Myriad Genetics Inc – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 49
Financial Announcements 49
Nov 07, 2017: Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results 49
May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results 50
Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results 52
Nov 01, 2016: Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results 54
Aug 09, 2016: Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results 56
May 03, 2016: Myriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results 58
Feb 02, 2016: Myriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results 60
Corporate Communications 62
Sep 29, 2016: Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy 62
Product News 63
Apr 17, 2017: Study Finds Wide Gap in Quality of BRCA1/2 Variant Classification Between Myriad Genetics and A Common Public Database 63
Oct 17, 2016: Myriad Will Present New Data on Its Variant Classification Program at the ASHG Annual Meeting 65
03/18/2016: Myriad Genetics Presented New Data on myChoice HRD at the Society for Gynecologic Oncology Annual Meeting 66
03/18/2016: The Myriad myRisk Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in Patients with Endometrial Cancer 67
03/15/2016: Myriad Presents myPlan Lung Cancer test at the 2016 USCAP Annual Meeting 68
03/15/2016: Myriad Presents Second Pivotal Validation Study for Its myPath Melanoma Test 69
03/08/2016: Myriad Advances Proprietary myVision Variant Classification Tools to a Broader Range of Cancer Risk Genes 70
Other Significant Developments 71
Oct 02, 2017: Myriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Month 71
Oct 21, 2016: Myriad Genetics Forms Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services to the Nation’s Largest Network of Community Oncologists 72
Oct 04, 2016: The US Oncology Network Selects Myriad Genetics as Preferred Provider for Hereditary Cancer Testing 73
May 18, 2016: Myriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List of Tables
Myriad Genetics Inc, Medical Equipment, Key Facts, 2017 2
Myriad Genetics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Myriad Genetics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Myriad Genetics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Myriad Genetics Inc, Deals By Market, 2011 to YTD 2017 9
Myriad Genetics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Rules-Based Medicine Acquires Intellectual Property Assets From Satoris 13
Myriad Genetics to Raise Funds through Venture Financing 14
AssureRx Health Raises Additional USD15 Million in Series D Financing 15
AssureRx Health Raises USD7 Million in Venture Financing 16
RainDance Technologies Raises US$20 Million In Series E Financing 18
Crescendo Bioscience Raises US$28 Million In Series D Financing 19
Assurex Health Secures USD12.5 Million in Series C Funding Round 21
Assurex Health Secures USD8 Million in Venture Funding Round 22
Crescendo Bioscience Raises US$56 Million In Series C Financing 23
Sividon Diagnostics Secures Venture Financing 24
AssureRx Plans To Raise US$10 Million In Series A Venture Financing 25
Myriad Genetics Enters into Licensing Agreement with Institut Curie and INSERM 26
Myriad Genetics Enters into Licensing Agreement With Children’s Medical Center 27
Myriad Genetics Enters into Licensing Agreement with University of Texas 28
Myriad Genetics Enters Into Licensing Agreement For RAD51C Gene 29
Myriad Genetics Enters Into Licensing Agreement With Chronix Biomedical 30
Sividon Diagnostics Enters into Co-Marketing Agreement with Virchow Labs and Ready Ruixin 31
Myriad Genetics Expands Agreement with AstraZeneca 32
Myriad Genetics Enters Into Co-Marketing Agreement With Sividon Diagnostics For EndoPredict Test 33
Myriad Enters Into Research Agreement With Janssen Research & Development 34
Myriad Genetics Expands Agreement with AstraZeneca for Olaparib 35
DaVita Enters Into Agreement With Myriad Genetics For Protein Biomarker Discovery 36
Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex Biomarker Kits 37
Myriad Genetics Acquires Assurex Health for USD348.5 Million 38
Myriad Genetics Acquires Sividon Diagnostics 40
Myriad Genetics Completes Acquisition Of Crescendo Bioscience For US$270 Million 41
Myriad Genetics Acquires Rules-Based Medicine 43
Myriad Genetics Inc, Key Competitors 45
Myriad Genetics Inc, Key Employees 46
Myriad Genetics Inc, Subsidiaries 47

★海外企業調査レポート[Myriad Genetics Inc (MYGN)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Spineology Inc：医療機器：M&Aディール及び事業提携情報
    Summary Spineology Inc (Spineology) is a medical device company that develops and designs spinal implants. The company offers products such as pedicular fixation system, interbody fusion system, deployable grafting system, amniotic fixation system, allografts, retractor system, liquid tissue matrix, …
  • H3 Biomedicine Inc-製薬・医療分野：企業M&A・提携分析
    Summary H3 Biomedicine Inc (H3 Biomedicine), a subsidiary of Eisai Co Ltd is a biopharmaceutical company that offers therapies. The company concentrates on discovery and early development of novel, targeted anti-cancer compounds. Its products include small-molecule drugs that are developed by utiliz …
  • Valeant Pharmaceuticals International, Inc.：企業の戦略・SWOT・財務情報
    Valeant Pharmaceuticals International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Valeant Pharmaceuticals International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Fortis Healthcare Ltd (FORTIS)：企業の財務・戦略的SWOT分析
    Fortis Healthcare Ltd (FORTIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Accu-Break Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Accu-Break Pharmaceuticals Inc (Accu-Break) is a developer and provider of pharmaceutical tablet technologies for accurate and customized dosing. The company provides services such as patented technologies, product differentiation, life cycle management, APIs solutions, product enhancement, …
  • Crownhaitai Holdings Co Ltd：企業の戦略・SWOT・財務情報
    Crownhaitai Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Crownhaitai Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Norfolk Southern Corp (NSC)：企業の財務・戦略的SWOT分析
    Norfolk Southern Corp (NSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Concho Resources Inc (CXO)：企業の財務・戦略的SWOT分析
    Summary Concho Resources Inc (Concho) is an oil and gas company. It acquires, develops, produces and explores oil and natural gas properties. The company owns and operates exploration assets in the Permian Basin region of Southeast New Mexico and West Texas, an onshore oil and natural gas basin in t …
  • Hexion Inc：企業の戦略的SWOT分析
    Hexion Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Denbury Resources Inc.：企業の戦略・SWOT・財務分析
    Denbury Resources Inc. - Strategy, SWOT and Corporate Finance Report Summary Denbury Resources Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Sartorius Stedim Biotech SA (DIM)：企業の財務・戦略的SWOT分析
    Sartorius Stedim Biotech SA (DIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Guadalupe Valley Electric Cooperative, Inc.：企業の戦略的SWOT分析
    Guadalupe Valley Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • Bajaj Corp Limited：企業の戦略・SWOT・財務分析
    Bajaj Corp Limited - Strategy, SWOT and Corporate Finance Report Summary Bajaj Corp Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Aptevo Therapeutics Inc (APVO)：製薬・医療：M&Aディール及び事業提携情報
    Summary Aptevo Therapeutics Inc (Aptevo), a subsidiary of Emergent Biosolutions Inc, is a biotechnology company that develops and commercializes oncology and hematology therapeutics. The company’s only marketed product Ixinity that is indicated to replace the missing clotting factor IX in adults and …
  • Interface Biologics Inc：医療機器：M&Aディール及び事業提携情報
    Summary Interface Biologics Inc (IBI) is a medical device company that develops transformative biomedical polymer technologies. The company offers anti-thrombogenic and combination drug delivery devices. Its anti-thrombogenic additives reduce thrombosis in blood contacting medical devices and polyme …
  • Therapure Biopharma Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Therapure Biopharma Inc (Therapure) is a biotherapeutics company that enhances patient care through its three divisions: therapure biomanufacturing, therapure innovations and evolve biologics. The company's therapure biomanufacturing division offers pipeline products such as TBI 301, TBI 302 …
  • J. Knipper and Company Inc：企業の戦略的SWOT分析
    J. Knipper and Company Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • China Digital Culture (Group) Ltd (8175)：企業の財務・戦略的SWOT分析
    China Digital Culture (Group) Ltd (8175) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Sumitomo Realty & Development Co., Ltd.：企業の戦略・SWOT・財務情報
    Sumitomo Realty & Development Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Realty & Development Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • MEDICREA Group (ALMED)：企業の財務・戦略的SWOT分析
    Summary MEDICREA Group (MEDICREA) is a medical equipment company that provides surgical solutions to neurosurgeons and orthopedic surgeons. The company designs, manufactures and distributes proprietary technologies related to patient specific spinal surgery. It offers products such as polyaxial spin …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆